Fig. 3: Radiographic Progression-Free Survival and Overall Survival Estimates of Patients with mCRPC Treated with BAT in Combination with Nivolumab. | Nature Communications

Fig. 3: Radiographic Progression-Free Survival and Overall Survival Estimates of Patients with mCRPC Treated with BAT in Combination with Nivolumab.

From: Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Fig. 3

Kaplan-Meier curves of A radiographic progression-free survival (rPFS) and B overall survival (OS) are shown. The median rPFS was estimated at 5.6 months (95% Confidence interval: 5.4–6.8 months). The median OS was estimated at 24.4 months. (95% Confidence interval: 17.6 – 31.1 months). The shaded area represents 95% confidence region.

Back to article page